Increased Expression of Micro-RNA-23a Mediates Chemoresistance to Cytarabine in Acute Myeloid Leukemia
Open Access
- 19 February 2020
- Vol. 12 (2), 496
- https://doi.org/10.3390/cancers12020496
Abstract
Resistance to chemotherapy is one of the primary obstacles in acute myeloid leukemia (AML) therapy. Micro-RNA-23a (miR-23a) is frequently deregulated in AML and has been linked to chemoresistance in solid cancers. We, therefore, studied its role in chemoresistance to cytarabine (AraC), which forms the backbone of all cytostatic AML treatments. Initially, we assessed AraC sensitivity in three AML cell lines following miR-23a overexpression/knockdown using MTT-cell viability and soft-agar colony-formation assays. Overexpression of miR-23a decreased the sensitivity to AraC, whereas its knockdown had the opposite effect. Analysis of clinical data revealed that high miR-23a expression correlated with relapsed/refractory (R/R) AML disease stages, the leukemic stem cell compartment, as well as with inferior overall survival (OS) and event-free survival (EFS) in AraC-treated patients. Mechanistically, we demonstrate that miR-23a targets and downregulates topoisomerase-2-beta (TOP2B), and that TOP2B knockdown mediates AraC chemoresistance as well. Likewise, low TOP2B expression also correlated with R/R-AML disease stages and inferior EFS/OS. In conclusion, we show that increased expression of miR-23a mediates chemoresistance to AraC in AML and that it correlates with an inferior outcome in AraC-treated AML patients. We further demonstrate that miR-23a causes the downregulation of TOP2B, which is likely to mediate its effects on AraC sensitivity.Keywords
Funding Information
- Austrian Science Fund (P26619-B19, P 31430-B26)
This publication has 65 references indexed in Scilit:
- Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysisBlood, 2017
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood, 2017
- Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAsInternational Journal of Molecular Sciences, 2016
- The role of microenvironment and immunity in drug response in leukemiaBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2016
- Acute Myeloid LeukemiaNew England Journal of Medicine, 2015
- Role of Microenvironment in Resistance to Therapy in AMLCurrent Hematologic Malignancy Reports, 2015
- Targeting the Microenvironment in Acute Myeloid LeukemiaCurrent Hematologic Malignancy Reports, 2015
- Acute myeloid leukemia in the real world: why population-based registries are neededBlood, 2012
- Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete RemissionJAMA, 2009
- Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia RegistryBlood, 2009